• Featured Product
  • KD/KO Validated

c-Met (Cytoplasmic) Polyclonal antibody

c-Met (Cytoplasmic) Polyclonal Antibody for IHC, IP, WB, ELISA

Host / Isotype

Rabbit / IgG


human and More (2)





Cat no : 25869-1-AP


AUTS9, c-Met, HGF receptor, HGF/SF receptor, HGFR, MET, Proto oncogene c Met, RCCP2, Scatter factor receptor, SF receptor, Tyrosine protein kinase Met

Tested Applications

Positive WB detected inA431 cells, HepG2 cells
Positive IP detected inHeLa cells
Positive IHC detected inhuman breast cancer tissue, human colon tissue, human liver cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:200-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB
Immunohistochemistry (IHC)IHC : 1:20-1:200
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 25869-1-AP is c-Met (Cytoplasmic) Fusion Protein expressed in E. coli.

Tested Reactivity human
Cited Reactivity human, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen c-Met (Cytoplasmic) fusion protein Ag23140
Full Name met proto-oncogene (hepatocyte growth factor receptor)
Calculated molecular weight 1390 aa, 155 kDa
Observed molecular weight 145 kDa
GenBank accession numberBC130420
Gene symbol MET
Gene ID (NCBI) 4233
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

c-Met (also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target (PMID: 26036285). The c-met receptor is a 190-kD glycoprotein consisting of a 145-kD membrane-spanning beta chain and a 50-kD alpha chain (PMID: 7806559). In Western blot, this antibody produces bands of unknown identity at 55 and 100 kDa.


Product Specific Protocols
WB protocol for c-Met (Cytoplasmic) antibody 25869-1-APDownload protocol
IHC protocol for c-Met (Cytoplasmic) antibody 25869-1-APDownload protocol
IP protocol for c-Met (Cytoplasmic) antibody 25869-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols




The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.

Authors - Xing Huang
  • KO Validated

Front Oncol

SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis.

Authors - Ruoyan Liu

Oxid Med Cell Longev

PMID: 31781338

Authors - Ya-Dong Liu

Kaohsiung J Med Sci

Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met.

Authors - Jia-Jie Chen

Thorac Cancer

CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.

Authors - Yichuan Chen

Cancer Manag Res

Adipose-Derived Stem Cells Promote Proliferation and Invasion in Cervical Cancer by Targeting the HGF/c-MET Pathway.

Authors - Yongning Zhai